AmerisourceBergen Story

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:5em;'>A</div>
ABC -- USA Stock  

USD 103.11  0.01  0.0097%

As many millenniums are trying to avoid healthcare space, it makes sense to go over AmerisourceBergen a little further and try to understand its current market patterns. As expected, AmerisourceBergen is starting to reaffirm its true potential as investors are becoming more and more confident in the future outlook. The returns on investing in AmerisourceBergen and the market returns of the last few months appear uncorrelated. The appearance of strong forward indicators of the company suggests a short-term price swing for investors of AmerisourceBergen. AmerisourceBergen is scheduled to announce its earnings today. The next earnings report is expected on the 4th of February 2021.
Published over two weeks ago
View all stories for AmerisourceBergen | View All Stories
Will AmerisourceBergen (NYSE:ABC) price continue to rise in December?
AmerisourceBergen's average rating is Hold from 9 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on AmerisourceBergen market sentiment investors' perception of the future value of AmerisourceBergen. Let us look at a few aspects of AmerisourceBergen technical analysis. Earning per share calculations of AmerisourceBergen is based on official Zacks consensus of 7 analysts regarding AmerisourceBergen's future annual earnings. Given the historical accuracy of 98.9%, the future earnings per share of the company is estimated to be 7.8743 with the lowest and highest values of 7.84 and 7.89, respectively. Please note that this consensus of annual earnings estimates for the firm is an estimate of EPS before non-recurring items and including employee stock options expenses.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of AmerisourceBergen. In general, we focus on analyzing AmerisourceBergen stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build AmerisourceBergen's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of AmerisourceBergen's intrinsic value. In addition to deriving basic predictive indicators for AmerisourceBergen, we also check how macroeconomic factors affect AmerisourceBergen price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.

How does AmerisourceBergen Stands against Peers?

Analyzing AmerisourceBergen competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to AmerisourceBergen across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out AmerisourceBergen Competition Details

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for AmerisourceBergen, but it might be worth checking our own buy vs. sell analysis

Exercise or conversion by Robert Mauch of 5417 shares of AmerisourceBergen subject to Rule 16b-3

Legal trades by AmerisourceBergen insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
AmerisourceBergen insider trading alert for exercise of restricted stock units by Robert Mauch, Executive Vice President, on 16th of November 2020. This event was filed by Amerisourcebergen Corp with SEC on 2020-11-16. Statement of changes in beneficial ownership - SEC Form 4. Robert Mauch currently serves as executive vice president, group president - pharmaceutical distribution & strategic global sourcing of AmerisourceBergen [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down the case for AmerisourceBergen

The entity has a beta of -0.1161. Let's try to break down what AmerisourceBergen's beta means in this case. As returns on the market increase, AmerisourceBergen returns are expected to increase less than the market. However, during the bear market, the loss on holding AmerisourceBergen will be expected to be smaller as well. The beta indicator helps investors understand whether AmerisourceBergen moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if AmerisourceBergen deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The current indifference towards the small price fluctuations of AmerisourceBergen could raise concerns from investors as the firm it trading at a share price of 105.42 on slow start in volume. The company management teams did not add any value to AmerisourceBergen investors in October. However, most investors can still diversify their portfolios with AmerisourceBergen to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently 1.52. The below-average Stock volatility is a good sign for longer-term investment options and for buy-and-hold investors.

Possible December recoup of AmerisourceBergen?

Current market risk adjusted performance is at 0.32. AmerisourceBergen exhibits very low volatility with skewness of 0.66 and kurtosis of 0.86. However, we advise investors to further study AmerisourceBergen technical indicators to make sure all market info is available and is reliable.

The Bottom Line

Whereas some firms within the medical distribution industry are still a little expensive, even after the recent corrections, AmerisourceBergen may offer a potential longer-term growth to investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither buy nor exit any shares of AmerisourceBergen at this time. The AmerisourceBergen risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to AmerisourceBergen.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of AmerisourceBergen. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com